About Alumis
Alumis is a company based in San Francisco (United States) founded in 2003.. Alumis has raised $529 million across 5 funding rounds from investors including General Atlantic, Piper Sandler and HBM Healthcare Investments. The company has 168 employees as of December 31, 2024. Alumis operates in a competitive market with competitors including Moderna, Forge Biologics, Aclaris Therapeutics, Annexon and Ventyx Biosciences, among others.
- Headquarter San Francisco, United States
- Employees 168 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alumis Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-294.23 M-89.84as on Dec 31, 2024
-
EBITDA
$-297.6 M-89.69as on Dec 31, 2024
-
Total Equity Funding
$529 M (USD)
in 5 rounds
-
Latest Funding Round
$40 M (USD), Post-IPO
Jul 17, 2024
-
Investors
General Atlantic
& 13 more
-
Employee Count
168
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alumis
Alumis is a publicly listed company on the NASDAQ with ticker symbol ALMS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Leadership Team
31 people
Software Development Team
9 people
Product Management Team
8 people
Operations Team
3 people
Finance and Accounting
3 people
Data Analysis and Operations Team
3 people
Sr. Team
2 people
Scientist Team
2 people
Unlock access to complete
Funding Insights of Alumis
Alumis has successfully raised a total of $529M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $40.0M
-
First Round
First Round
(05 May 2021)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Post-IPO - Alumis | Valuation |
investors |
|
| Mar, 2024 | Amount | Series C - Alumis | Valuation | Foresite Capital , Samsara BioCapital | |
| Jun, 2023 | Amount | Series B - Alumis | Valuation | General Atlantic |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alumis
Alumis has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include General Atlantic, Piper Sandler and HBM Healthcare Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location | |
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alumis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Alumis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alumis Comparisons
Competitors of Alumis
Alumis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Forge Biologics, Aclaris Therapeutics, Annexon and Ventyx Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alumis
Frequently Asked Questions about Alumis
When was Alumis founded?
Alumis was founded in 2003 and raised its 1st funding round 18 years after it was founded.
Where is Alumis located?
Alumis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Alumis?
Martin Babler is the current CEO of Alumis.
Is Alumis a funded company?
Alumis is a funded company, having raised a total of $529M across 5 funding rounds to date.
How many employees does Alumis have?
As of Dec 31, 2024, the latest employee count at Alumis is 168.
What does Alumis do?
Alumis was founded in 2003 and is based in San Francisco, United States. Focus is placed on the development of therapeutics targeting autoimmune diseases within the biotechnology sector. Operations involve research into inhibitors like the lead candidate SK-001, a TYK2 pseudokinase allosteric inhibitor for psoriasis. The TYK2 gene is recognized for encoding a tyrosine kinase that mediates inflammation and autoimmune responses.
Who are the top competitors of Alumis?
Alumis's top competitors include Moderna, Forge Biologics and Annexon.
Is Alumis publicly traded?
Yes, Alumis is publicly traded on NASDAQ under the ticker symbol ALMS.
Who are Alumis's investors?
Alumis has 14 investors. Key investors include General Atlantic, Piper Sandler, HBM Healthcare Investments, AyurMaya, and Foresite Capital.
What is Alumis's ticker symbol?
The ticker symbol of Alumis is ALMS on NASDAQ.